Related Experiment Video
Updated: Feb 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Abstract:
These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events. A mild long-term reduction in blood pressure and LDL cholesterol has the potential to significantly reduce the lifetime risk of cardiovascular events. In the final section the article discusses options for improving patient adherence to antihypertensive and lipid treatment and the new available fixed combinations for these diseases.Key words: arterial hypertension - cardiovascular prevention - dyslipidemia - fixed combinations - treatment.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension II: Pathophysiology
Hypertension V: Nursing Management

